Clinical Trial Update: Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update evaluating SBRT with Cardonilizumab and Lenvastinib for unresectable hepatocellular carcinoma with portal vein tumor thrombus (Phase 1/2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Portal Vein Tumor Thrombosis

Drugs mentioned

• Cardonilizumab (Cardonilizumab)
• Lenvastinib (Lenvastinib)
• SBRT (stereotactic body radiotherapy)

Snippet

Sponsor: First Affiliated Hospital of Guangxi Medical University | Conditions: Hepatocellular Carcinoma Non-resectable, Portal Vein Tumor Thrombus | Phase 1, Phase 2 | Status: UNKNOWN